Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3550 clinical trials
A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

The purpose of the study is to evaluate safety and immunogenicity of various respiratory syncytial virus (RSV) pre-Fusion (preF)-based vaccine components followed by expanded safety evaluation and durability/revaccination evaluation of the selected RSV preF-based vaccine formulation in participants aged greater than or equal to (>=) 60 years in stable health.

Accepts healthy volunteers
  • 1 views
  • 16 Jun, 2022
  • 9 locations
A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.

Accepts healthy volunteers
  • 0 views
  • 20 Apr, 2022
  • 16 locations
A Study of Acute Respiratory Infections in Global Outpatient Setting (ARGOS)

participants presenting with acute respiratory infections (ARIs) in outpatient settings during the influenza/RSV season and to evaluate the association between lower respiratory tract disease (LRTD) and ARI

  • 0 views
  • 29 May, 2022
  • 11 locations
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

This trial consists of three parts, Part A, Part B, and Part C, and will evaluate the safety and immunogenicity of a third booster injection of the multivalent vaccine BNT162b2 (B.1.1.7 + B.1.617.2), and the safety and immunogenicity of a third booster injection of the monovalent vaccine BNT162b2 (B.1.617.2) or …

Accepts healthy volunteers
  • 57 views
  • 03 Jul, 2022
  • 25 locations
Selective High Frequency Oscillatory Ventilation (HFOV) for Neonates

Neonatal respiratory distress syndrome (RDS) remains a major respiratory disorder for the increasing preterm population, and its incidence has been confirmed to be increased gradually with

FIO2
acute respiratory distress
high frequency oscillatory ventilation
assisted breathing
pulmonary surfactant
  • 7 views
  • 24 Feb, 2021
  • 1 location
Minor Stroke Therapy Evaluation (MOSTE)

Stroke represents the fourth leading cause of death in industrialized nations, after heart disease, cancer, and chronic lower respiratory disease. Approximately one-quarter of the patients

diffusion weighted imaging
heart disease
thrombectomy
ischemic stroke
cancer
  • 0 views
  • 12 May, 2022
  • 1 location
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for …

measurable disease
immunomodulator
treatment regimen
stage iv non-small cell lung cancer
progressive disease
  • 34 views
  • 26 May, 2022
  • 80 locations
Smoking Cessation Programme in Workplaces in Hong Kong (Phase )

Smoking causes cardiovascular and respiratory diseases, cancers and diabetes, and it has been a leading risk factor for death globally. Despite the availability of smoking cessation services

  • 0 views
  • 01 May, 2021
  • 1 location
Comparison of Procedural Yield of Bronchoalveolar Lavage Using Three Different Techniques in Subjects Undergoing Flexible Bronchoscopy (BAL-3T)

compare the three methods of obtaining BAL in subjects undergoing BAL for various respiratory diseases

  • 0 views
  • 30 Jun, 2022
  • 2 locations
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib.

EGFR
egfr t790m
osimertinib
  • 0 views
  • 19 Apr, 2022
  • 16 locations